OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
12
Results
Show all
Save search
Copy query
Show results for
Unknown
(12)
Publication Date
Release Date
2025
(2)
2022
(2)
2020
(2)
2018
(2)
2021
(1)
2019
(1)
2017
(1)
2013
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Association of anticoagulant use with clinical outcomes from crizotinib in ALK- and ROS1-rearranged advanced non-small cell lung cancers: A retrospective analysis of PROFILE 1001.
Not available
S-EPMC9741966
|
biostudies-literature
Cite
Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
Not available
S-EPMC8524025
|
biostudies-literature
Cite
Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer.
Not available
S-EPMC7539325
|
biostudies-literature
Cite
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.
Not available
S-EPMC6056984
|
biostudies-literature
Cite
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With
ROS1
-Positive Advanced NSCLC.
Not available
S-EPMC9558051
|
biostudies-literature
Cite
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.
Not available
S-EPMC7249761
|
biostudies-literature
Cite
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
Not available
S-EPMC6637370
|
biostudies-literature
Cite
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
Not available
S-EPMC6267942
|
biostudies-literature
Cite
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Not available
S-EPMC8500676
|
biostudies-literature
Cite
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Not available
S-EPMC10649377
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets